Inclusion Criteria:

• Read and signed the Informed Consent Document
• Female or male, 18 to 61 years old (up to 62nd birthday)
• Females must agree to exercise adequate birth control from the time of the screening procedures to one month after the last vaccination
• Willingness and ability to return for all follow-up visits and blood collections for the duration of the study
• Ability to understand and comply with planned study procedures
• Agree to complete the Participant Diary (Appendix G) and to report concomitant medications and AEs during the study period
• Have two intact upper arms with sufficient subcutaneous and intramuscular tissue in the deltoid regions for vaccine administration.
• Potential participants with a history of the following conditions remain eligible for study enrollment:

gestational diabetes; treated, controlled, uncomplicated hypertension; treated hypo- or hyperthyroidism; cured nonmetastatic cancer; disease-free for 5 years (excluding hematologic malignancies); localized skin cancer, resected (including squamous cell and basal cell carcinomas, participants with a history of melanoma must be disease-free for 5 years); exercise-induced bronchospasm; mild asthma: use of inhalers only for control of symptoms is acceptable (Persons who have required hospitalization for asthma within the previous 2 years or those who require chronic or frequent oral/parenteral steroids will not be eligible; use of low to medium doses of inhaled steroids; history of coronary artery disease, asymptomatic (NYHA Function Class I), on a stable medical regimen. Persons meeting these criteria must be at least 2 years post-myocardial infarction, cardiac bypass surgery, and/or percutaneous coronary intervention (e.g., angioplasty, stent placement, etc) in order to qualify. Persons with a history of cardiac disease must be under the care of a physician.

Exclusion Criteria:

• Prior history of anthrax or immunization against anthrax
• Known allergy to aluminum hydroxide, formaldehyde, benzethonium chloride, or latex
• Pregnancy or plans to become pregnant for the duration of the study and/or not agreeing to exercise adequate birth control from the time of the screening procedures to one month after the last vaccination
• Received experimental products within 30 days prior to study entry
• Plans to receive experimental products within 60 days after study entry
• Received a live vaccine outside this trial within 30 days prior to study entry
• Received an inactivated vaccine outside this trial within 14 days prior to study entry
• Plans to receive a live vaccine outside this trial within 60 days after study entry
• Plans to receive an inactivated vaccine outside this trial within 42 days after study entry
• Received immunosuppressive therapy within 30 days prior to study entry
• Plans to receive immunosuppressive therapy within 60 days after study entry
• Use of cytotoxic therapy in the previous 5 years
• Plans to receive cytotoxic therapy within 60 days after study entry
• Receipt of parenteral immunoglobulin or blood products within three months of study
• Plans to receive parenteral immunoglobulin or blood products within 60 days after study entry
• Active malignancy or history of metastatic or hematologic malignancy
• Any current diabetes
• Cardiovascular disease with a significant likelihood of progression over 5 years, including any person with a history of cardiomyopathy or congestive heart failure
• Moderate to severe asthma, chronic obstructive pulmonary disease, other significant pulmonary disease
• Persons who are using high doses of inhaled steroids
• Clinically recognized hepatic or renal insufficiency
• Inflammatory, vasculitic, or rheumatic disease including systemic lupus erythematosis, polymyalgia rheumatica and rheumatoid arthritis, scleroderma
• Known HIV, hepatitis B or hepatitis C infection
• Other conditions known to produce or be associated with immune suppression
• Neuropathy or other evolving neurologic condition
• Unstable and/or moderate to severe mental illness
• Ongoing drug abuse/dependence (including alcohol)
• Seizure disorder
• In addition to the conditions listed above, moderate or severe illness and/or oral temperature higher than 100.4˚F within 3 days of injection or chronic condition that, in the opinion of the investigator, would render injection unsafe or would interfere with evaluations would be considered a temporary exclusion criterion.